Regeneron (REGN) Tops Q1 EPS by $1.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports First Quarter 2022 Financial and Operating Results
May 4, 2022 6:30 AM EDTTARRYTOWN, N.Y., May 4, 2022 /PRNewswire/ --
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 25%First quarter 2022 EYLEA® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021First quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS(a) of $11.49Dupixent approved in EU for children aged 611 years with severe asthma; FDA priority review... More